» Articles » PMID: 27014277

Impact of MIF Gene Promoter Variations on Risk of Rheumatic Heart Disease and Its Age of Onset in Saudi Arabian Patients

Overview
Journal Front Immunol
Date 2016 Mar 26
PMID 27014277
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Although macrophage migration inhibitory factor (MIF) has consistently been shown to be an important immune modulator, data on the association between MIF promoter variations and the risk of developing rheumatic heart disease (RHD) remain inconclusive. RHD is an important complication of streptococcal infections in the Middle East, not least in Saudi Arabia, and identifying risk markers is an important priority. Therefore, we investigated the association between two functional MIF promoter variations and RHD susceptibility and severity in Saudi patients: the MIF-173G > C substitution (rs755622) and the MIF-794 CATT5-8 tetranucleotide repeat (rs5844572). Three hundred twenty-six individuals (124 RHD patients and 202 age-, sex-, and ethnically matched healthy controls) were genotyped using allelic discrimination and fragment analysis. Data were analyzed with respect to disease susceptibility, severity, sex, and age of onset. There was a significantly lower frequency of 173C allele carriage in RHD patients compared to controls [odds ratio (OR) = 0.47; 95% confidence intervals (CIs) = 0.28-0.77; p = 0.003]. Interestingly, the 173C allele was associated with late disease onset (p = 0.001). The 794 5-repeat allele was associated with decreased RHD risk (OR = 0.56; 95% CIs = 0.38-0.82; p = 0.003). In contrast, the 794 6-repeat allele was associated with increased risk of RHD (OR = 1.7; 95% CIs = 1.2-2.5; p = 0.002). MIF promoter variations appear to have a dual role in RHD, with 173C allele non-carriers at higher risk of developing RHD at a younger age. These results require further validation in larger multi-ethnic cohorts, and functional studies are necessary to understand the underlying molecular mechanisms driving the at-risk phenotype.

Citing Articles

Impact of the -173G/C variant on cardiovascular disease risk: a meta-analysis of 9,047 participants.

Fouda H, Ibrahim W, Shi Z, Alahmadi F, Almohammadi Y, Al-Haidose A Front Cardiovasc Med. 2024; 11:1323423.

PMID: 38476376 PMC: 10929265. DOI: 10.3389/fcvm.2024.1323423.


The Impact of Gene Variants on Acute-Phase Reactants in Children with Rheumatic Heart Disease.

Almazroea A, Yousef S, Ahmad S, AlHiraky H, Al-Haidose A, Abdallah A Diagnostics (Basel). 2023; 13(10).

PMID: 37238156 PMC: 10217348. DOI: 10.3390/diagnostics13101672.


Association of gene polymorphisms with pemphigus vulgaris: a case-control study with comprehensive review of the literature.

Gupta P, Joshi N, Uprety S, Dogra S, De D, Handa S Int J Clin Exp Pathol. 2021; 14(11):1080-1089.

PMID: 34900076 PMC: 8661066.


Association between MIF gene promoter rs755622 and susceptibility to coronary artery disease and inflammatory cytokines in the Chinese Han population.

Luo J, Fang B, Du G, Liu F, Li Y, Tian T Sci Rep. 2021; 11(1):8050.

PMID: 33850223 PMC: 8044220. DOI: 10.1038/s41598-021-87580-6.


The Genetic Control of the Rheumatic Heart: Closing the Genotype-Phenotype Gap.

Abdallah A, Abu-Madi M Front Med (Lausanne). 2021; 8:611036.

PMID: 33842495 PMC: 8024521. DOI: 10.3389/fmed.2021.611036.


References
1.
Xia W, Zhang F, Xie C, Jiang M, Hou M . Macrophage migration inhibitory factor confers resistance to senescence through CD74-dependent AMPK-FOXO3a signaling in mesenchymal stem cells. Stem Cell Res Ther. 2015; 6:82. PMC: 4453287. DOI: 10.1186/s13287-015-0076-3. View

2.
Ma H, Wang J, Paul Thomas D, Tong C, Leng L, Wang W . Impaired macrophage migration inhibitory factor-AMP-activated protein kinase activation and ischemic recovery in the senescent heart. Circulation. 2010; 122(3):282-92. PMC: 2907453. DOI: 10.1161/CIRCULATIONAHA.110.953208. View

3.
Al-Harbi K, Almuzaini I, Morsy M, Abdelaziz N, Al-Balawi A, Abdallah A . Angiotensin-converting enzyme gene insertion/deletion polymorphism in Saudi patients with rheumatic heart disease. Saudi Med J. 2015; 36(2):176-80. PMC: 4375694. DOI: 10.15537/smj.2015.2.10267. View

4.
Remenyi B, Carapetis J, Wyber R, Taubert K, Mayosi B . Position statement of the World Heart Federation on the prevention and control of rheumatic heart disease. Nat Rev Cardiol. 2013; 10(5):284-92. DOI: 10.1038/nrcardio.2013.34. View

5.
Abdallah A, Alnuzha A, Al-Mazroea A, Eldardear A, AlSamman A, Almohammadi Y . IL10 Promoter Polymorphisms are Associated with Rheumatic Heart Disease in Saudi Arabian Patients. Pediatr Cardiol. 2015; 37(1):99-105. DOI: 10.1007/s00246-015-1245-y. View